Results 91 to 100 of about 19,507 (228)
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
Neuropsychiatric Disease and Treatment, 2013 Michele Jara,1 Graham Barker,2 Herbert R Henney 3rd1 1Acorda Therapeutics, Inc, Ardsley, NY, USA; 2Biogen Idec, Inc, Maidenhead, Berkshire, UK Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained ...
Jara M, Barker G, Henney 3rd HR
doaj
Regulating risks in pharmaceutical law : the need of an optimal interplay between products safety and products liability [PDF]
, 2011 Published online: 7 June 2011The aim of this paper is to call for the need of a theoretical model of pharmaceutical products safety in which the two systems of regulation and liability operate complementarily. The question is why two legal tools that are
RIZZI, Marco
core
Educating Pharmacy Students to Improve Quality (EPIQ) in Colleges and Schools of Pharmacy [PDF]
, 2012 Objective. To assess course instructors’ and students’ perceptions of the Educating Pharmacy Students and Pharmacists to Improve Quality (EPIQ) curriculum. Methods.
Gilligan, Adrienne M. +9 more
core +2 more sources
Therapeutics and Clinical Risk Management, 2012 Gary Bloomgren, Bjørn Sperling, Kimberly Cushing, Madé WentenBiogen Idec Inc., Weston, MA, USABackground: Intramuscular interferon beta-1a (IFNβ-1a), a multiple sclerosis (MS) therapy that has been commercially available ...
Bloomgren G +3 more
doaj
EFFECTIVENESS AND SAFETY OF 1% PIMECROLIMUS CREAM AS APPLIED AMONG CHILDREN WITH ATOPIC DERMATITIS
Педиатрическая фармакология, 2009 The article highlights the findings of the open surveying uncontrolled multicentric postmarketing research to study the effectiveness and safety of 1% pimecrolimus cream as applied among children aged over months, suffering from atopic dermatitis.
K.E. Efendieva +2 more
doaj +2 more sources
Vascular Health and Risk Management, 2013 Yasufumi Kuroda,1 Chie Hirayama,2 Hitoshi Hotoda,2 Yasuhiro Nishikawa,2 Akinori Nishiwaki21Daiichi Sankyo Pharma Development, Edison, NJ, USA; 2Daiichi Sankyo Company, Limited, Tokyo, JapanPurpose: Edoxaban is an oral, once-daily, selective, direct ...
Kuroda Y +4 more
doaj
Journal of Arrhythmia, 2019 Background Apixaban, a non‐vitamin K oral anticoagulant (NOAC), was approved in Japan in 2012 for the prevention of thromboembolic events in patients with nonvalvular atrial fibrillation (NVAF).
Hiroshi Inoue +5 more
doaj +1 more source
What is the addiction risk associated with tramadol? [PDF]
, 2005 Tramadol (Ultram, generic and with acetaminophen in Ultracet) carries a risk of substance abuse (strength of recommendation [SOR]: B, based on case report surveillance programs).
Mackler, Leslie, McDiarmid, Todd
core
Incentivizing the Utilization of Pharmacogenomics in Drug Development [PDF]
, 2012 Pharmacogenomics, the study and development of compounds according to how an individual’s genes affects the body’s response to drugs, holds enormous promise for increasing the safety and efficiency of drug development while decreasing adverse reactions ...
Koch, Valerie Gutmann
core +1 more source
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
Therapeutic Advances in Neurological Disorders, 2017 Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over
Barry A. Singer
doaj +1 more source